| Identification | Back Directory | [Name]
C-021 dihydrochloride | [CAS]
1784252-84-1 | [Synonyms]
Inhibitor,C 021 dihydrochloride,CCL22,CCR4,C021,C021 dihydrochloride,CCR,C 021,CC chemokine receptor,inhibit,C-021,GTPγS,chemotaxis | [Molecular Formula]
C27H42ClN5O2 | [MOL File]
1784252-84-1.mol | [Molecular Weight]
504.12 |
| Hazard Information | Back Directory | [Description]
Chemokine (C-C motif) receptor 4 (CCR4) antagonist is an antagonist of CCR4.1 It inhibits activation of CCR4 by chemokine (C-C motif) ligand 22 (CCL22) in a [35S]GTPγS assay and also inhibits chemotaxis in human and mouse CCR4-expressing B300-19 cells (IC50s = 18, 140, and 39 nM, respectively). CCR4 antagonist inhibits microglial activation in the cortex in a mouse model of hepatic encephalopathy induced by the neurotoxin azoxymethane when administered at a dose of 1 mg/kg per day.2 It reduces azoxymethane-induced increases in Il6 and Il1b expression in mouse cortex. CCR4 antagonist reduces mechanical and thermal sensitivity in a mouse model of type I diabetes induced by streptozotocin when administered intrathecally at doses ranging from 10 to 30 μg/animal.3 | [Uses]
C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM[1]. | [in vivo]
The potency of C-021 (Compound 1b) is evident after subcutaneous administration in the murine oxazolone-induced contact hypersensitivity test, a known model of acute skin inflammation. When C-021 is administered orally, however, very little inhibition is observed[1].
C-021 (1 mg/kg; i.p.; daily; for 3 days) significantly less microgliosis in acute liver failuremice[2]. | Animal Model: | Male C57Bl/6 mice (20-25 g) with acute liver failure[2] | | Dosage: | 1 mg/kg | | Administration: | i.p.; daily; for 3 days | | Result: | Significantly less microgliosis, and significantly reduced the pERK1/2 to tERK1/2 ratio. |
| [IC 50]
CCR4 | [storage]
Desiccate at RT | [References]
1. Yokoyama, K., Ishikawa, N., Igarashi, S., et al. Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines Bioorg. Med. Chem. 16(14),7021-7032(2008).
2. McMillin, M., Frampton, G., Thompson, M., et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline J. Neuroinflammation 11,121(2014).
3. Bogacka, J., Ciapa?a, K., Pawlik, K., et al. Blockade of CCR4 diminishes hypersensitivity and enhances opioid analgesia - Evidence from a mouse model of diabetic neuropathy Neuroscience 441,77-92(2020). |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
|